Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD)
Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD)
复制标题
DOI：
10.1017/s109285291200051x
复制
发表时间：
2012-09-01
期刊：
影响因子：
3.3
通讯作者：
Nakamura, Jun
中科院分区：
文献类型：
--
作者：
Katsuki, Asuka;Yoshimura, Reiji;Nakamura, Jun
物体。我们研究了脑源性神经营养因子(BDNF)基因Val66Met多态性与日本重度抑郁障碍(MDD)患者米氮平疗效的关系。我们还检测了米氮平对这些患者血清脑源性神经营养因子和血浆儿茶酚胺代谢产物水平的影响。84例符合DSM-IV-TR诊断MDD标准的患者仅接受米氮平治疗4周。用直接测序法检测该区域BDNF Val66Met基因的多态性，用ELISA法测定血清BDNF水平，用高效液相色谱-电子捕获检测法测定血浆儿茶酚胺代谢产物水平。米氮平治疗4周后，有反应者的血清BDNF水平显著升高，而无效者的血清BDNF水平显著降低。未发现两种基因型(Val/Val或Met携带者)与T4时对米氮平的反应或T0时血清BDNF水平之间的关联。米氮平不改变血浆高香草酸(HVA)或3-甲氧基-4-羟基苯甘醇(MHPG)水平。血清BDNF水平的动态变化，而不是血浆HVA和MHPG水平的动态变化，反映了米氮平治疗的反应；然而，抑郁症患者的BDNF Val66Met基因多态性与米氮平治疗的特定反应或基线血清BDNF水平无关。血清BDNF水平，而不是血浆HVA或MHPG水平，以及BDNF Val66Met基因多态性与MDD的米氮平疗效相关。2012年1月31日收到；2012年4月27日受理
Object. We investigated an association between the polymorphism of brain-derived neurotrophic factor (BDNF) gene Val66Met and the response to mirtazapine in Japanese patients with major depressive disorder (MDD). We also examined mirtazapine's effects on the serum BDNF and plasma levels of catecholamine metabolites in these patients.Methods. Eighty-four patients who met the DSM-IV-TR criteria for MDD were treated with only mirtazapine for 4 weeks. The BDNF Val66Met polymorphism was detected by direct sequencing in the region, and serum BDNF levels and plasma levels of catecholamine metabolites were measured by ELISA and HPLC-ECD, respectively.Results. Mirtazapine treatment for 4 weeks significantly increased serum BDNF levels in the responders, whereas nonresponders showed significant decreases. No association was found between either of the two genotypes (Val/Val vs. Met-carriers) and the response to mirtazapine at T4 or the serum BDNF levels at T0. Mirtazapine did not alter the plasma levels of homovanillic acid (HVA) or 3-methoxy-4-hydroxyphenylglycol (MHPG).Discussion. The dynamics of serum BDNF levels, but not plasma levels of HVA and MHPG, reflect the response to mirtazapine treatment; the BDNF Val66Met polymorphism in patients with depression is, however, associated with neither a particular response to mirtazapine treatment nor baseline serum BDNF levels.Conclusion. Serum BDNF levels, but not plasma levels of HVA or MHPG, and BDNF Val66Met polymorphism are related to the mirtazapine response in MDD. Received 31 January 2012; Accepted 27 April 2012